<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948763</url>
  </required_header>
  <id_info>
    <org_study_id>V941-001</org_study_id>
    <secondary_id>V941-001</secondary_id>
    <nct_id>NCT03948763</nct_id>
  </id_info>
  <brief_title>A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and tolerability and establish a preliminary recommended
      Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab
      infusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Anticipated">November 19, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (Up to 21 days)</time_frame>
    <description>The following toxicities graded for severity using NCI Common Terminology for Adverse Events (CTCAE), Version 4.0 will be considered a DLT if judged by the investigator to be possibly related to study investigational products: 1) Grade 4 nonhematologic toxicity (ie. not a laboratory finding). 2) Grade 4 hematologic toxicity lasting ≥ 7 days, except thrombocytopenia: 3) Grade 4 thrombocytopenia of any duration 4) Grade 3 thrombocytopenia associated with clinically significant bleeding 5) Any nonhematologic AE ≥ Grade 3 in severity, with some exceptions 6) Any Grade 3 or Grade 4 nonhematologic laboratory value that meets one of the study criteria 7) Febrile neutropenia Grade 3 or Grade 4 8) Prolonged delay (&gt; 2 weeks) in initiating Cycle 2 due to treatment-related toxicity. 9) Any treatment-related toxicity that causes the participant to discontinue treatment during Cycle 1. 10) Grade 5 toxicity 11) Any other clinically significant toxicity judged to be a DLT by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 25 months</time_frame>
    <description>Number of participants who experienced an AE. An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuations</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Number of participants who discontinued from study due to an AE. An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>ORR is assessed by the investigator based on Response Rate Assessed by Modified Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) and RECIST for immune-based therapeutics (iRECIST) following administration of V941 in combination with pembrolizumab. Objective response is a confirmed complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutant KRAS Specific T cells</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Presence of and changes in the quantity of mutant KRAS specific T cells in the blood.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>T-cell receptor (TCR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>T-cell receptor (TCR) clonality and diversity in the periphery and tumor.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neoplasms</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>V941 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V941(mRNA-5671/V941) administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V941 + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V941(mRNA-5671/V941) administered IM Q3W for 9 cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V941</intervention_name>
    <description>V941 administered IM, Q3W for 9 3-week cycles</description>
    <arm_group_label>V941 + Pembrolizumab</arm_group_label>
    <arm_group_label>V941 Monotherapy</arm_group_label>
    <other_name>mRNA-5671/V941</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg, IV for 35 3-week cycles</description>
    <arm_group_label>V941 + Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 2 Only

        - Has a histologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC),
        non-mismatch repair deficient/microsatellite instability-high tumors colorectal cancers
        (non-MSI-H CRC), or pancreatic adenocarcinoma, and confirmed HLA types HLA-A11:01 and/or
        HLA C08:02 (and/or potentially other additional HLA types to be specified).

        NSCLC: Participants must have been tested for mutations affecting EGFR and/or anaplastic
        lymphoma kinase (ALK). Participants with ALK or epidermal growth factor receptor
        (EGFR)-positive NSCLC must have had recurrent or progressive disease (PD) after treatment
        with the corresponding inhibitor and current standard of care, in any sequence.

        Non-MSI-H CRC: Participant tumors must have been locally tested for MSI and have been found
        to be non-MSI-H.

        All

          -  Has a histologically confirmed advanced or metastatic KRAS 4MUT+ (G12D, G12V, G13D or
             G12C) (4 prevalent KRAS mutant antigens in solid tumors) solid tumor identified by
             local laboratory testing, and who have received, or been intolerant to, or ineligible
             for all treatment known to confer clinical benefit.

          -  A male participant must agree to use study-approved contraception during the treatment
             period and for at least 120 days after the last dose of study intervention and refrain
             from donating sperm during this period.

          -  A female participant was not be pregnant, not breastfeeding, and at not be a woman of
             childbearing potential (WOCBP) OR if a WOCBP, agrees to follow study-approved
             contraceptive guidance during treatment period and for at least 120 days after the
             last dose of study intervention.

          -  Have measurable disease per RECIST 1.1 as assessed by the local site
             investigator/radiology. Lesions situated in a previously irradiated area are
             considered measurable if progression has been demonstrated in such lesions.

          -  For Part 1 only: Cutaneous lesions can be considered in addition to imaging, but
             measurable disease should be defined by radiologic assessment.

          -  Have an evaluable archival tumor sample to submit for analysis. Formalin-fixed,
             paraffin embedded (FFPE) tissue blocks are preferred to slides.

          -  Have adequate organ function

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale.

        Exclusion Criteria:

          -  A WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization
             or treatment allocation

          -  Has an active infection requiring therapy.

          -  Has a history of interstitial lung disease.

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive
             drugs) except vitiligo or resolved childhood asthma/atopy.

          -  Has not fully recovered from any effects of major surgery or has evidence of
             detectable infection. Surgeries that required general anesthesia must be completed at
             least 2 weeks before first study treatment administration. Surgery requiring
             regional/epidural anesthesia must be completed at least 72 hours before first study
             treatment administration and participants should be recovered.

          -  Has had chemotherapy, definitive radiation, or biological cancer therapy within 4
             weeks (2 weeks for palliative radiation) prior to the first dose of study therapy,
             non-cytotoxic small molecule therapeutics within 5 half-lives (or 2 weeks, whichever
             is longer) prior to the first dose of study treatment, or has not recovered to Common
             Toxicity Criteria for Adverse Events (CTCAE) Grade 1 or better from any adverse events
             that were due to cancer therapeutics administered more than 4 weeks earlier (this
             includes participants with previous immunomodulatory therapy with residual
             immune-related adverse events).

          -  Has received a live-virus vaccine within 30 days of planned treatment start. Seasonal
             flu vaccines that do not contain live virus are permitted.

          -  Has received hematopoietic colony-stimulating growth factors (eg, granulocyte-colony
             stimulating factor, granulocyte-macrophage-colony stimulating factor, macrophage
             colony stimulating factor) within 2 weeks prior to the first dose of study
             intervention.

          -  Discontinued from therapy with an anti-programmed cell death protein 1 (anti-PD-1),
             anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or
             co-inhibitory T-cell receptor (TCR; eg, cytotoxic T lymphocyte-associated antigen 4
             (CTLA-4), CD137 (4‐1BB, Tumor necrosis factor‐receptor superfamily 9 [TNFSF9]), and OX
             40 (TNFRSF4), due to a Grade 3 or higher immune-related adverse event (irAE).

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 28 days prior to the first dose of
             study intervention.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior the first dose of study drug.

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 2 years.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
             reactive) or known active Hepatitis C virus (defined as HCV ribonucleic acid (RNA)
             [qualitative] is detected) infection.

          -  Has a known history of HIV.

          -  Has a known psychiatric or substance abuse disorder that would interfere with
             cooperating with the requirements of the study.

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of study intervention.

          -  Has had an allogenic tissue/solid organ transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope ( Site 1002)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>626-218-3419</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco ( Site 1006)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-353-7084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven ( Site 1005)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>203-737-2445</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute ( Site 7000)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>877-691-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>START San Antonio ( Site 1004)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-593-5265</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC ( Site 1001)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>253-428-8738</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>solid tumors</keyword>
  <keyword>therapeutic vaccine</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>KRAS</keyword>
  <keyword>mRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

